Last reviewed 2026-04-19 · How we verify

NETICONAZOLE

Phase 2 active Small molecule

NETICONAZOLE is a neticonazole drug. It is currently in Phase 2 development.

Neticonazole works by interacting with a specific target to produce its therapeutic effect.

Neticonazole is a small molecule drug in the neticonazole class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, key safety considerations and pharmacokinetic properties such as half-life and bioavailability are not well established. Further research is needed to fully understand this drug. Its ownership and development history are also unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NETICONAZOLE
Drug class	neticonazole
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Unfortunately, the exact way neticonazole works is not well understood, but it is thought to interact with a specific target to produce its therapeutic effect. This interaction can help to treat certain conditions by altering the way the body functions. However, more research is needed to fully understand this process.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NETICONAZOLE CI brief — competitive landscape report
NETICONAZOLE updates RSS · CI watch RSS

Frequently asked questions about NETICONAZOLE

What is NETICONAZOLE?

NETICONAZOLE is a neticonazole drug.

How does NETICONAZOLE work?

Neticonazole works by interacting with a specific target to produce its therapeutic effect.

What drug class is NETICONAZOLE in?

NETICONAZOLE belongs to the neticonazole class. See all neticonazole drugs at /class/neticonazole.

What development phase is NETICONAZOLE in?

NETICONAZOLE is in Phase 2.

Drug class: All neticonazole drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing